BRD4 and AL amyloidosis: Our previous study and Zhang et al. have both demonstrated that ARV-825 has promising activity against pre-clinical models of multiple myeloma by degrading BRD4 protein and subsequently leads to downregulation of BRD4 target genes, including MYC (29, 30).